Asahi Kasei Pharma To Expand Naftopidil Market Share
This article was originally published in PharmAsia News
Executive Summary
Asahi Kasei Pharma will expand market share for benign prostate hyperplasia drug Flivas (naftopidil) in Japan. The company obtained the drug's intellectual property rights from Roche Diagnostics. Asahi Kasei sees a stronger demand for the drug since the sales of competeing drugAvishot (naftlopidil), manufactured by Organon Japan (now Schering Plough) will be halted by Schering Plough by March 2010. Asahi also plans to increase medical representatives by 50 percent to 900 by 2014 and double sales from ¥50 billion to ¥100 billions by 2015. To speed new drug development, the company aims to increase research and development investment by ¥2 billion each year for 2009 and 2010, and reach ¥14 billion in 2010. (Click here for more - Japanese language